Treatment With Valoctocogene Roxaparvovec in a Patient With Severe Hemophilia A Led to Sustained Normal FVIII Levels
Valoctocogene roxaparvovec can offer durable FVIII expression in severe hemophilia A. This case provides valuable insights into personalised immunosuppression therapy with a favourable outcome for long-term efficacy and safety.
Authors
- Claudia Klein
- Ulrich Spengler (ORCID: https://orcid.org/0000-0002-8746-2413)
- Kerstin Herbst (ORCID: https://orcid.org/0009-0005-9753-0570)
- Georg Goldmann
- Thilo Albert
- C Strassburg
- P Lutz
- Johannes Oldenburg
- Behnaz Pezeshkpoor
Institutions
- University of Bonn (DE)
- University Hospital Bonn (DE)
- Institute for Transfusion Medicine (US)
Publication Details
- Journal
- Haemophilia
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1111/hae.70261
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00